Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This patent grant is significant as it strengthens Greenland Mines' position in the rapidly advancing field of gene therapy for neurodegenerative conditions. The Klotho protein has been linked to cognitive function and longevity, making it a promising target for diseases that currently have limited treatment options. By securing patent protection in Canada, the company expands its market potential and validates its approach among regulatory bodies.
For Greenland Mines, which operates both a mining division focused on rare earths and precious metals in Greenland and a biotech division, this development underscores its dual strategy. The company is building a multi-asset platform with exposure to critical materials while advancing therapeutic candidates. The biotech division's progress, particularly with KLTO-202 for ALS, could provide significant value if clinical trials succeed.
Investors and stakeholders can view the full press release at https://ibn.fm/x2pHA. More updates on GRML are available in the company’s newsroom at https://ibn.fm/GRML.
The implications of this patent extend beyond immediate IP protection. It positions Greenland Mines to potentially license the technology, pursue partnerships, or develop its own therapies. The company's timeline for KLTO-101 and KLTO-202 indicates a structured approach to development, with GMP manufacturing already underway for the ALS candidate. This suggests progress toward clinical trials, which could be a catalyst for the company.
However, challenges remain. Gene therapy is a complex field with high development costs and regulatory hurdles. The company will need to demonstrate safety and efficacy in trials. Additionally, its mining operations face geopolitical and environmental risks. Nevertheless, the patent grant is a positive step that could attract investor interest and strategic collaborations.
In summary, Greenland Mines' Canadian patent for Klotho gene therapy technology marks a milestone in its biotech division, potentially offering new hope for neurodegenerative disease patients and strengthening the company's overall value proposition.
